Niraparib Maintenance Treatment Significantly Increased Outcomes for Ovarian Cancer Patients

Niraparib Maintenance Treatment Significantly Increased Outcomes for Ovarian Cancer Patients
Ovarian cancer patients with recurrent, platinum-sensitive disease may benefit greatly from niraparib maintenance treatment, according to data from a Phase 3 trial in which niraparib significantly prolonged patients' progression-free survival compared to placebo. Findings of the study, "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer," were presented recently for the first time at the European Society for Medical Oncology (ESMO) 2016 Congress, and published in The New England Journal of Medicine. "There are limited treatment options in recurrent ovarian cancer," said lead author Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet, Copenhagen University Hospital, Denmark and medical director of the Nordic Society of Gynaecological Oncology (NSGO), in a press release. "Cumulative toxicity with platinum-based chemotherapy and lack of additional benefit limits its use. We then pause treatment until the next relapse and start combination chemotherapy," he said. "The current options for maintenance therapy in the EU are bevacizumab [marketed as Avastin], which can only be given once and improves progression-free survival by just a few months, and the PARP inhibitor olaparib [marketed as Lynparza], which is only approved in patients with a germline BRCA mutation (about 10-15% of ovarian cancer patients). No maintenance therapy is approved outside the EU," he added. Niraparib, a PARP inhibitor, induces cancer cell death by preventing the proper repair of da
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *